This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

+2.22%

-2.82%

-0.61%

First Look Media, Inc.

FRST

0.00

Neurosense Therapeutics Ltd.

NRSN

0.00

Putnam New York Investment Grade Municipal Trust

PMN

0.00

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

D. Boral Capital analyst Jason Kolbert initiated coverage on NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) with a Buy rating and announced a price target of $14. NeuroSense Therapeutics shares closed at $1.0438 on Friday. See how other analysts view this stock.
Maxim Group analyst Jason McCarthy initiated coverage on ProMIS Neurosciences, Inc. (NASDAQ:PMN) with a Buy rating and announced a price target of $3. ProMIS Neurosciences shares closed at $0.5020 on Friday. See how other analysts view this stock.
Maxim Group initiated coverage on Primis Financial Corp. (NASDAQ:FRST) with a Buy rating and announced a price target of $1. Primis Finl shares closed at $8.96 on Friday. See how other analysts view this stock.

Considering buying NRSN stock? Here’s what analysts think:

Read This Next:

5 Stock Picks Last Week From Wall Street’s Most Accurate Analysts

Photo via Shutterstock

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Stock Valuations | Potential rise of up to 471.43%! Canaccord Genuity raised its target price for GUTS stock by $8, while maintaining its buy recommendation.

ProMIS Neurosciences (NASDAQ:PMN) Will Have To Spend Its Cash Wisely

ProMIS Neurosciences Announces 1-For-25 Reverse Stock Split, Effective Nov. 28

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

FDA Clears NeuroSense Therapeutics to Launch Phase 3 Trial of PrimeC for ALS

FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment

D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

Dow Jumps 300 Points; Waldencast Shares Plunge